20-F: I-Mab Reports Fiscal Year 2023 Results, Divests Greater China Assets

I-Mab reports its 2023 financial results and finalizes the divestiture of its Greater China assets to focus on its global pipeline.

Summary

• I-Mab, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, and the completion of the divestiture of its Greater China assets.
• The company is now focused on developing and commercializing immunotherapies for cancer.
• In April 2024, I-Mab closed the divestiture of its Greater China assets and business operations to I-Mab Biopharma (Hangzhou) Co., Ltd. for up to US$80 million, contingent on future milestones.
• As a result, I-Mab will no longer consolidate the divested entities, assets, and businesses from the second quarter of 2024.
• The company's cash, cash equivalents, and short-term investments totaled RMB2.3 billion (US$321.8 million) as of December 31, 2023, compared to RMB3.5 billion in 2022.
• Net losses for 2023 were RMB1,465.7 million (US$206.4 million), compared to RMB2,507.3 million in 2022.
• The company expects its financial condition and results of operations to be materially affected by the divestiture, with historical results not indicative of future performance.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the divestiture provides financial resources, the company is still operating at a loss and faces significant challenges in a competitive industry. The focus on a smaller pipeline could be positive, but it also increases the risk associated with those assets.

Positives

• Divestiture of Greater China assets provides I-Mab with adequate near-term funding to support its focused pipeline.
• Uliledlimab shows promising results in NSCLC patients with high PD-L1 and CD73 expression.
• Givastomig demonstrates efficacy and a potentially differentiated safety profile in early trials.
• The company has regained full global rights to develop and commercialize certain CD47 compounds and products, including lemzoparlimab.

Negatives

• The company incurred net losses of RMB1,465.7 million (US$206.4 million) in 2023.
• Historical results are not indicative of future financial condition or results of operations due to the divestiture.
• The company faces significant risks related to the transition of its business focus to the U.S. market.

Risks

• The company has a limited operating history, which may make it difficult to evaluate its current business and predict its future performance.
• The company may need to obtain additional financing to fund its operations.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company faces intense competition and rapid technological change.
• The company relies on third parties to conduct its pre-clinical studies and clinical trials.
• The trading price of the company's ADSs may be volatile.
• The company may be subject to litigation and regulatory proceedings.

Future Outlook

I-Mab expects its financial condition and results of operations to be materially affected by the divestiture of its Greater China assets and business operations, with historical results not indicative of future performance. The company will focus on its global oncology clinical assets and explore global partnership opportunities.

Industry Context

The biopharmaceutical industry is highly competitive, with companies facing intense competition and rapid technological change. I-Mab is competing with major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.

Comparison to Industry Standards

• The most advanced CD73 antibody currently in clinical development is oleclumab (MEDI-9447) sponsored by Medimmune/AstraZeneca, which has initiated a Phase 3 study in NSCLC patients.
• Arcus Biosciences has reported encouraging results in their Phase 1b/2 trial of quemliclustat, a small molecule CD73 inhibitor, in combination with zimberelimab plus chemotherapy in patients with pancreatic cancer.
• Other companies are developing PD-L1 x 4-1BB bispecific antibodies, including Genmab and Inhibrx.

Legal Proceedings

• Non-participating shareholders of I-Mab Hangzhou have initiated legal proceedings against I-Mab Hong Kong and the company in connection with the divestiture transaction.

Stakeholder Impact

• Shareholders will experience a shift in the company's focus and potential dilution from future capital raises.
• Employees may face uncertainty due to the transition and potential restructuring.
• Customers (patients) may see changes in the availability of certain drugs in Greater China.

Next Steps

• Submit an IND for uliledlimab in combination with chemotherapy and checkpoint inhibitors in newly diagnosed patients with advanced NSCLC in the first half of 2024.
• Continue to sponsor a Phase 1 study of givastomig in combination with chemotherapy and a PD-1 inhibitor in patients with treatment-nave gastric, gastro-esophageal junction and esophageal cancer.
• Develop a CLDN18.2 immunohistochemistry assay for patient selection.
• Explore potential global partnership opportunities for givastomig.
• ABL Bio will present the top-line Phase 1 clinical data for ragistomig at a major medical conference in the first half of 2024.
• Evaluate opportunities to further develop lemzoparlimab and related drugs, as well as potential business partnership with other global pharmaceutical and bio-tech companies in the future.

Key Dates

Keywords

I-Mab, financial results, divestiture, Greater China, immunotherapy, uliledlimab, givastomig, ragistomig, lemzoparlimab, biopharmaceutical